Summary:
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with major depressive disorder (MDD) who responded to acute treatment with vortioxetine 10 mg.
Qualified Participants Must:
• Be between 18 and 75 years of age, inclusive
•
Suffer from recurrent major depressive disorder (MDD) as the primary diagnosis
•
Have had at least 2 other major depressive episodes (MDEs) before the current episode
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.